

The underlying purpose of 10 CFR 50.82(b)(6) is to describe the requirements that must be met for license termination, one of which is that the results of the terminal survey and other documentation show that the facility and site meet the requirements for release. These survey results and documentation form part of the basis for terminating the license. In this case, the remaining reactor components (the facility) will be released, but the site will not be released. Because the site will continue to be subject to the NRC license for the TRIGA reactor, application of the rule that the terminal survey and other documentation must show that the site is suitable for release is not necessary in order to terminate the license.

IV

For the foregoing reasons, the NRC staff has concluded that not requiring a terminal radiation survey and associated documentation that demonstrate that the site is suitable for release as a condition of license termination will not present an undue risk to public health and safety and is consistent with the common defense and security. The NRC staff has determined that there are special circumstances present, as specified in 10 CFR 50.12(a)(2), in that application of part of 10 CFR 50.82(b)(6)(ii) is not necessary in order to achieve the underlying purpose of this regulation.

Accordingly, the Commission has determined that, pursuant to 10 CFR 50.12(a), an exemption is authorized by law, will not endanger life or property or common defense and security, and is otherwise in the public interest. Therefore, the Commission hereby grants an exemption from the requirements of 10 CFR 50.82(b)(6)(ii) that a terminal radiation survey and associated documentation demonstrates that the site is suitable for release as needed as a condition of Operating License No. R-25 termination.

Pursuant to 10 CFR 51.32, the Commission has determined that the granting of this exemption will not have a significant effect on the quality of the human environment (62 FR 11936).

For further details with respect to this action, see (1) the application for termination of Amended Facility Operating License No. R-25, dated July 17, 1990, as supplemented; (2) the Commission's safety evaluation related to the termination of the license; (3) the environmental assessment and finding of no significant impact; and (4) the Commission's Order terminating Amended Facility Operating License No. R-25. Each of these items is

available for public inspection at the Commission's Public Document Room, 2120 L Street, NW., Washington, D.C. 20037.

Copies of items (2), (3), and (4) may be obtained upon receipt of a request addressed to the U.S. Nuclear Regulatory Commission, Washington, D.C. 20555-0001, Attention: Director, Division of Reactor Program Management.

This exemption is effective upon issuance.

Dated at Rockville, Maryland, this 14th day of March 1997.

For the Nuclear Regulatory Commission.

Samuel J. Collins,

Director, Office of Nuclear Reactor Regulation.

[FR Doc. 97-7338 Filed 3-21-97; 8:45 am]

BILLING CODE 7590-01-P

Nominations of New Members of the Advisory Committee on the Medical Uses of Isotopes

AGENCY: U.S. Nuclear Regulatory Commission

ACTION: Call for nominations.

SUMMARY: The U.S. Nuclear Regulatory Commission is inviting nominations for three positions on the Advisory Committee on the Medical Uses of Isotopes (ACMUI) to fill current and upcoming committee vacancies. One position is for a physician practicing nuclear cardiology. The second position is for a patients' rights and care advocate. The third position is for an individual with State or local government perspective.

DATES: Nominations are due May 23, 1997.

ADDRESSES: Submit nominations to: The Office of Personnel, Attn: Ms. Jude Himmelberg, Mail Stop T2D32, U.S. Nuclear Regulatory Commission, Washington, DC 20555.

FOR FURTHER INFORMATION CONTACT: William B. McCarthy, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555, Telephone: 301-415-7894.

SUPPLEMENTARY INFORMATION: The ACMUI advises NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on changes in NRC rules, regulations, and guides concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and providing

technical assistance in licensing, inspection, and enforcement cases.

Committee members possess the medical and technical skills needed to address evolving issues. Currently, the ACMUI membership consists of: (a) three practicing physicians; (b) a physician representing the U.S. Department of Health and Human Services, Food and Drug Administration; (c) a nuclear pharmacist; (d) two medical physicists (nuclear medicine and therapy); (e) a health care administrator; (f) a certified medical dosimetrist; and (g) a patients' rights and care advocate (whose term expires September 30, 1997). Presently, the specialties of the physicians on the ACMUI are: therapeutic radiology, with expertise in teletherapy and brachytherapy (two), and nuclear medicine research (one). The staff is in the process of finalizing the appointment of a nominee for the position of nuclear medicine physician.

The U.S. Nuclear Regulatory Commission is inviting nominations for three positions on the Advisory Committee on the Medical Uses of Isotopes (ACMUI). One position is for a physician practicing nuclear cardiology. The second position is for a patients' rights and care advocate. The third position is for an individual with State or local government perspective.

Nominees must include four copies of their resumes, describing their educational and professional qualifications, and provide their current addresses and telephone numbers.

All new committee members will serve 3-year terms, with possible reappointment to an additional 3-year term.

Nominees must be U.S. citizens and be able to devote approximately 80 hours per year to committee business. Members will be compensated and reimbursed for travel (including per diem in lieu of subsistence), secretarial, and correspondence expenses. Nominees will undergo a security background check and will be required to complete financial disclosure statements, to avoid conflict-of-interest issues.

Dated at Rockville, Maryland, this 18th day of March, 1997.

For the U.S. Nuclear Regulatory Commission.

Andrew L. Bates,

Advisory Committee Management Officer, Office of the Secretary of the Commission.

[FR Doc. 97-7316 Filed 3-21-97; 8:45 am]

BILLING CODE 7590-01-P